GET DAILY SIGNALSMicrobot Medical (MBOT): Examining the LIBERTY System's Role in Endovascular Procedures
Key Takeaways
- MBOT is the Nasdaq ticker for Microbot Medical Inc., a commercial-stage medical device company focused on endovascular robotics.
- The company's flagship product, the LIBERTY Endovascular Robotic System, is the first FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
- Microbot Medical was founded in 2010 and is headquartered in Hingham, Massachusetts, with a research and development heritage in Israel.
- The company received FDA 510(k) clearance for LIBERTY in September 2025 and began full U.S. commercialization in 2026.
- Microbot Medical targets a large U.S. market of roughly 2.5 million peripheral endovascular procedures annually, positioning itself in the emerging field of medical robotics.
Company Overview
Microbot Medical Inc. develops robotic technology aimed at improving minimally invasive endovascular procedures. Traded on the Nasdaq under the ticker MBOT, the company has drawn attention as an early player in surgical and interventional robotics. Its main innovation, the LIBERTY Endovascular Robotic System, seeks to enhance precision in catheter-based work while limiting physician radiation exposure and physical demands. From what I see, this places Microbot at the overlap of medical devices, robotics, and outpatient care.
Background and Operations
Microbot Medical was founded in 2010 and is based in Hingham, Massachusetts, with notable research and development roots in Israel. As a commercial-stage company, it has only recently moved from development into revenue generation. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the medical device space.
Core Technology and Products
The standout offering is the LIBERTY Endovascular Robotic System. This single-use, remotely operated platform handles guidewires, microcatheters, and similar devices inside the vasculature. It earned 510(k) clearance from the FDA in September 2025, marking it as the first such cleared disposable robotic system for peripheral endovascular procedures. The single-use design supports a different approach from larger capital-heavy robots, focusing on per-procedure use that could ease adoption for hospitals.
Business Approach and Market Reach
Revenue comes mainly from selling the disposable systems for individual procedures, with additional distribution deals in international markets and for federal facilities. The company has carried substantial research costs and operated at a net loss historically, typical for firms scaling in this sector. It targets the peripheral endovascular market, estimated at about 2.5 million annual U.S. procedures, and has expanded focus toward interventional cardiology and neurovascular areas. LIBERTY has supported procedures such as prostatic artery embolization and Y-90 radioembolization. In my view, the single-use model offers potential for recurring revenue that stands apart from one-time equipment sales.
Investor Perspective
Investors track MBOT as an early-stage name in medical robotics growth. Trends toward minimally invasive care and attention to physician radiation exposure provide support. The intellectual property portfolio, now including dozens of patents, along with work alongside institutions like Corewell Health and Emory University, adds to the long-term case. One thing that stands out is how the business model aligns with recurring procedural demand.
Risks to Consider
Early-stage medical device firms like this carry notable risks. Limited revenue history, ongoing losses, and reliance on a single main product create concentration concerns. Regulatory hurdles remain, including further clearances abroad, while competition from larger robotics players is intense. Adoption rates at hospitals are not assured, and smaller companies often face dilution risks from financing needs along with broader healthcare spending pressures.
Integrating AI Tools in Analysis
When evaluating opportunities in medical devices or related sectors, I find Tickeron’s AI Screener helpful for quickly filtering stocks by technical signals, fundamentals, and industry patterns. It allows me to surface ideas that align with specific strategies without sifting through thousands of names manually. This keeps my research process efficient while focusing on the details that matter for a name like MBOT.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
MBOT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for MBOT turned positive on October 22, 2026. Looking at past instances where MBOT's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MBOT's RSI Indicator exited the oversold zone, 22 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
Following a +9.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBOT advanced for three days, in 150 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 45 cases where MBOT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBOT as a result. In 76 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBOT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
MBOT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MBOT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. MBOT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.082) is normal, around the industry mean (4.142). P/E Ratio (-4.440) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (263.158) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBOT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which specializes in the research, design, development and commercialization of micro-robotics assisted medical technologies
Industry MedicalNursingServices
Advertisement